NZ255043A

NZ255043A - Lipidized proteins and compositions thereof and their use in targeting proteins to intracellular compartments and enhancing organ uptake of them

Info

Publication number: NZ255043A
Application number: NZ255043A
Authority: NZ
Inventors: Bernard Malfroy-Camine
Original assignee: Eukarion Inc
Priority date: 1992-07-13
Filing date: 1993-07-13
Publication date: 1997-03-24
Also published as: FI941169A; FI941169A0; KR20030097604A; OA09893A; EP0607408A4; JPH07502753A; KR100372119B1; CA2118586A1; EP0607408A1; RU2157239C2; WO1994001131A1; AU4772793A; RU94024566A

Description

<div class="application article clearfix" id="description"> New Zealand No. International No. 255043 PCT/US93/06599 TO BE ENTERED AFTER ACCEPTANCE AND PUBLICATION Priority dates: International filing date: 13| | ^ 3 Classification: Co"lK»M-|oO",ColKi|)o7» Abl K381II*, A(el 12,OT, flfel KSI f IO) Publication date: 2 <1 MAR 199? Journal No.: '4-if Class Cont: .?! i£7 r? NEW ZEALAND PATENTS ACT 1953 COMPLETE SPECIFICATION Title of invention: Transvascular and intracellular delivery of lipiaized proteins Name, address and nationality of applicant(s) as in international application form: EUKARION, INC, of 6F Alfred Circle, Bedford, Massachusetts 01730, USA^ <\ Li 5 WO 94/01131 25 5 0 4 PCT/US93/06599 transvascular and intracellular delivery of lipidized proteins 5 FIELD OF THE INVENTION The invention provides methods for targeting a protein, such as an antibody, to intracellular compartments in a eukaryotic cell, methods for enhancing organ uptake of 10 proteins, pharmaceutical compositions of modified proteins for use in human therapy, and methods for manufacturing modified proteins. The modified proteins of the invention comprise an attached lipid portion, wherein one or more acyl groups are linked to the protein through a carbohydrate side-chain and 15 various covalent linkage chemistries which are provided. BACKGROUND OF THE INVENTION Many naturally-occurring or modified proteins have been proposed as diagnostic and/or therapeutic agents for use 20 in humans and domestic animals. However, proteins are generally only poorly transported across vascular endothelial membranes, if at all, and usually cannot traverse cellular membranes to gain access to intracellular compartments. Thus, for example, antibodies can be raised against purified 25 intracellular proteins, such as transcription factors, intracellular enzymes, and cytoarchitectural structural proteins, but such antibodies generally are not ^ble to enter intact cells and bind to the intracellular antigen targets unless the cell membrane is disrupted. 30 The advent of monoclonal antibody technology in the mid 1970's heralded a new age of medicine. For the first time, researchers and clinicians had access to essentially unlimited quantities of uniform antibodies capable of binding to a predetermined antigenic site and having various 35 immunological effector functions. These proteins, known as "monoclonal antibodies" were thought to hold great promise in, e.g.. the removal of harmful cells, microbial pathogens, and viruses in vivo. Methods allowing the development of specific monoclonal antibodies having binding specificities directed WO 94/01131 against almost any desired antigenic epitope, including antigens which are located in intracellular compartments in intact cells, promised a cornucopia of medicinal "magic bullets". 5 Unfortunately, the development of appropriate therapeutic products based on monoclonal antibodies, as well as polyclonal antisera, has been severely hampered by a number of drawbacks inherent in the chemical nature of naturally-occurring antibodies. First, antibodies are generally not 10 able to efficiently gain access to intracellular locations, as immunoglobulins are not able to traverse the plasma membrane of cells, and are typically only internalized, if at all, as a consequence of inefficient endocytotic mechanisms. Second, antibodies do not generally cross vascular membranes (e.g., 15 subendothelial basement membrane), hampering the efficient uptake of antibodies into organs and interstitial spaces. Therefore, therapies for many important diseases could be developed if there were an efficient method to get specific, biologically active immunoglobulin molecules across capillary 20 barriers and into intracellular locations. For example, the life cycle of a retrovirus such as HIV involves intracellular replication wherein several viral-encoded polypeptides essential for production of infectious virions from an infected cell could potentially be inhibited or blocked if 25 specific monoclonal antibodies reactive with the viral-encoded proteins could readily gain access to the intracellular locations where retroviral replication occurs. Immunoliposomes have been produced as a potential targeted delivery system for delivering various molecules 30 contained in the liposome to a targeted cell. Immunoliposomes employ immunoglobulins as targeting agents, wherein an acylated immunoglobulin is anchored in the lipid bilayer of the liposome to target the liposome to particular cell types that have external antigens that are bound by the acylated 35 immunoglobulin(s) of the immunoliposomes (Connor and Huang (1985) J. Cell Biol. 101: 582; Huang, L. (1985) Biochemistry 2±: 29; Babbitt et al. (1984) Biochemistry 23: 3920; Connor et WO 94/01131 PCT/ US93/06599 25 5 0 4 3 al. (1984) Proc. Natl. Acad. Sci. (U.S.A.) 81: 1715; Huang et al. (1983) J. Biol, chem. 258: 14034; Shen et al. (1982) Biochim. Blphvs. Acta 689: 31; Huang et al. (1982) Biochim. Blophvs. Acta 716: 140; Huang et al. (1981) J. Immunol. 5 Methods ££: 141; and Huang et al. (198 0) J. Biol. Chem. 255: 8015). Immunoliposomes generally contain immunoglobulins which are attached to acyl substituents of a liposome bilayer through a crosslinking agent such as N-hydroxysuccimide and which thus become anchored in the liposome lipid bilayer. 10 Hence, the crosslinked immunoglobulin is linked to the liposome and serves to target the liposomes to specific cell types bearing a predetermined external antigen by binding to the external cellular antigen. While such methods may serve to target liposomes to particular cell types, immunoliposomes 15 suffer from several important drawbacks that have limited their application as drug-delivery vehicles, particularly for delivering proteins to intracellular locations. Attempts have been made at modifying proteins so as to facilitate their transport across capillary barriers and 20 into cells (EP 0 329 185), however, no completely satisfactory method has yet been reported in the art. Chemical modification of proteins, such as antibodies, by non-specific "cationization" to enhance transvascular and intracellular delivery of proteins, has been reported (WO 9^19971). 25 However, present methods for making cationized immunoglobulins lead to a significant loss of binding affinity (approximately about 90 percent) of a cationized immunoglobulin for binding to its predetermined epitope as compared to the comparable non-cationized immunoglobulin. Generally, cationization 3 0 involves carbodiimide linkage of a diamine, such as putrescine or hexanediamine, to the carboxylates of aspartate and glutamate residues in the immunoglobulin polypeptide sequence. These chemical modifications of primary amino acids likely disrupt the secondary and tertiary structure of the 35 immunoglobulin sufficiently to account for the loss in binding affinity. Also, present methods produce some degree of cationization in glutamate and aspartate residues located in M 7. • --C! 2 3 DEC 1996 WO 94/01131 255 043 PCT/US93/06599 -the variable domain of an immunoglobulin chain, which results in significant loss of binding affinity and/or specificity. Chemical modification of small molecules has also been proposed as a method to augment transport of small 5 bioactive compounds. Feigner (W091/17242) discloses forming lipid complexes consisting of lipid vesicles and bioactive substances contained therein. Feigner et al. (W091/16024) discloses cationic lipid compounds that are allegedly useful for enhancing transfer of small bioactive molecules in plants 10 and animals. Liposomes and polycationic nucleic acids have been suggested as methods to deliver polynucleotides into cells. Liposomes often show a narrow spectrum of cell specificities, and when DNA is coated externally on to them, the DNA is often sensitive to cellular nucleases. Newer 15 polycationic lipospermines compounds exhibit broad cell ranges (Behr et al., (1989) Proc. Natl. Acad. Sci. USA 86:69821 and DNA is coated by these compounds. In addition, a combination of neutral and cationic lipid has been indicated as a method for transfection of animal cells (Rose et al., (1991) 20 BioTechnicmes 10:5201. Other approaches to enhancing delivery of drugs, particularly across the blood-brain barrier, utilize pharmacologic-based procedures involving drug latentiation or the conversion of hydrophilic drugs into lipid-soluble drugs. 25 The majority of the latentiation approaches involve blocking the hydroxy1, carboxyl and primary amine groups on the drug to make it more lipid-soluble and therefore more easily transported across the blood-brain barrier. Pardridge and Schimmel, U.S. Patent 4,902,505, disclose chimeric peptides 30 for enhancing transport by receptor-mediated transcytosis. Thus, there exists a need in the art for methods of facilitating transport of specific proteins, such as antibodies, across capillary barriers and into cells, and for pharmaceutical compositions of such immunoglobulins for 35 treating human and veterinary diseases which are amenable to treatment with intracellular proteins and targeting agents like monoclonal antibodies. 255 043 WO 94/01131 PCT/US93/06599 5 summary of the invention The prior art method of increasing antibody transport into cells by attaching a cationic substituent to the primary polypeptide sequence of an immunoglobulin by a 5 relatively nonspecific linkage chemistry have been observed to produce detrimental alterations in the secondary, tertiary, and/or quaternary structure of the protein. These structural alterations apparently cause the loss of binding affinity observed in cationized antibodies. To overcome this, the 10 present invention provides methods wherein lipid substituents are linked to a protein, such as an immunoglobulin, typically by covalent linkage to a carbohydrate side chain of the protein such that the lipid substituent does not substantially destroy the biological activity of the protein (e.g., antigen 15 binding). The invention provides methods for producing lipidized proteins, generally by lipidization of a carbohydrate moiety on a glycoprotein or glycopeptide. In general, the methods of the invention are used for attaching a 20 lipid, such as a lipoamine, to a polypeptide, typically by covalent linkage of the lipid to a carbohydrate moiety on a protein, wherein the carbohydrate moiety generally is chemically oxidized and reacted with a lipoamine to form a lipidized protein. The resultant lipidized protein generally 25 has advantageous pharmacokinetic characteristics, such as an increased capacity to cross vascular barriers and access parenchymal cells of various organs and an increased ability to access intracellular compartments. In one aspect of the invention, lipidization of proteins, such as antibodies 30 directed against transcription factors (e.g., Fos, Jun, AP-1, OCT-i, NF-AT), enhances intranuclear localization of the lipidized protein(s). The invention also provides methods for producing lipidized antibodies that are efficiently transported across 35 capillary barriers and internalized into mammalian cells in vivo. The methods of the invention relate to methods for chemically attaching at least one lipid substituent (e.g., WO 94/01131 255 0 43 PCT/ US93/06599 lipoamine) to a carbohydrate substituent on an immunoglobulin to produce a carbohydrate-linked lipidized immunoglobulin, wherein the lipidized immunoglobulin is capable of intracellular localization. In alternate embodiments of the 5 invention, at least one lipid substituent (e.g., lipoamine) is covalently attached to a non-carbohydrate moiety on a protein or polypeptide (e.g., by formation of an amide linkage with a Asp or Glu residue side-chain carboxyl substituent or a thioester linkage with a Cys residue). Also, a fatty acid can 10 be linked to an Arg or Lys residue by the side-chain amine substituents. Similarly, lipid substitutents can be covalently attached to peptidomimetic compounds. Peptide analogs are commonly used in the pharmaceutical industry as non-peptide 15 drugs with properties analogous to those of the template peptide. These types of non-peptide compound are termed "peptide mimetics" or "peptidomimetics" (Fauchere, J. (1986) Adv. Drug Res. 29; Veber and Freidinger (1985) TINS p.392; and Evans et al. (1987) J. Med. Chem 30: 1229, which are 20 incorporated herein by reference) and are usually developed with the aid of computerized molecular modeling. Peptide mimetics that are structurally similar to therapeutically useful peptides may be used to produce an equivalent therapeutic or prophylactic effect. Generally, 25 peptidomimetics are structurally similar to a paradigm polypeptide (i.e., a polypeptide that has a biological or pharmacological activity), but have one or more peptide linkages optionally replaced by a linkage selected from the group consisting of: -CH2NH-, -CH2S-, -CH2-CH2-, -CH=CH- (cis 30 and trans) , -COCH2-, -CH(OH)CH2-, and -CH2SO-, by methods known in the art and further described in the following references: Spatola, A.F. in "Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins," B. Weinstein, eds., Marcel Dekker, New York, p. 267 (1983); Spatola, A.F., Vega Data (March 35 1983), Vol. 1, Issue 3, "Peptide Backbone Modifications" (general review); Morley, J.S., Trends Pharm Sci (1980) pp. 463-468 (general review); Hudson, D. et al., Int J Peot Prot 255043 WO 94/01131 PCT/US93/06599 7 Res (1979) 11:177-185 (-CH2NH-, CH2CH2-) ; Spatola, A.F. et al., Life Sci (1986) 22.: 1243-1249 (-CH2-S) ; Hann, M.M., J Chem Soe Perkin Trans I (1982) 307-314 (-CH-CH-, cis and trans); Almquist, R.G. et al., J Med Chem (1980) 22:1392-1398 (-COCH2-5 ); Jennings-White, C. et al., Tetrahedron Lett (1982) 22:2533 (-COCH2—); Szelke, M. et al., European Appln. EP 45665 (1982) CA: 22:39405 (1982) (-CH (OH) CH2-); Holladay, M.W. et al., Tetrahedron Lett (1983) 24:4401-4404 (-C(OH)CH2-); and Hruby, V.J., Life Sci (1982) 21:189-199 (-CH2-S-) ; each of which is 10 incorporated herein by reference. A particularly preferred non-peptide linkage is -CH2NH-. Such peptide mimetics may have significant advantages over polypeptide embodiments, including, for example: more economical production, greater chemical stability, enhanced pharmacological properties (half-15 life, absorption, potency, efficacy, etc.), altered specificity (e.g., a broad-spectrum of biological activities), reduced antigenicity, and others. Lipidization of peptidomimetics usually involves covalent attachment of one or more acyl chains, directly or through a spacer (e.g., an amide 20 group), to non-interfering position(s) on the peptidomimetic that are predicted by quantitative structure-activity data and/or molecular modeling. Such non-interfering positions generally are positions that do not form direct contacts with the macromolecules(s) (e.g., receptors) to which the 25 peptidomimetic binds to produce the therapeutic effect. Lipidization of peptidomimetics should not substantially interfere with the desired biological or pharmacological activity of the peptidomimetic. The invention also relates to therapeutic and 30 diagnostic compositions of lipidized proteins, such as lipidized antibodies, that can cross vascular membranes and enter the intracellular compartment, particularly lipidized antibodies that bind to intracellular immunotherapeutic targets, such as viral-encoded gene products that are 35 essential components of a viral life cycle (e.g., HIV-1 Tat protein), to intracellular antigens that are biologically active (e.g., an oncogene protein such as c-fos, c-src, c-myc, 25 5 0 A3 WO 94/01131 PCT / US93/06599 8 c-lck (p56), c-fyn (p59), and c-abl), and/or to transmembrane or extracellular antigens (e.g., polypeptide hormone receptors such as an IL-2 receptor, PDGF receptor, EGF receptor, NGF receptor, GH receptor, or TNF receptor). Other proteins which 5 can be targeted by lipidized antibodies include, but are not limited to, the following: c-ras p21, c-her-2 protein, c-raf, any of the various G proteins and/or G-protein activating proteins (GAPs), transcription factors such as NF-AT, calcineurin, and cis-trans prolyl isomerases. The lipidized 10 antibodies can be used to localize a diagnostic reagent, such as a radiocontrast agent or magnetic resonance imaging component, to a specific location in the body, such as a specific organ, tissue, body compartment, cell type, neoplasm, or other anatomical structure (e.g., a pathological lesion). 15 The lipidized antibodies can also be used to localize linked therapeutic agents, such as chemotherapy drugs, radiosensitizing agents, radionuclides, antibiotics, and other agents, to specific locations in the body. Alternatively, the lipidized antibodies of the invention can be used 20 therapeutically for neutralizing (i.e, binding to and thereby inactivating) an intracellular target antigen, such as HIV-l Tat proteint a transmembrane or membrane-associated antigen target (e.g., 7-glutamyltranspeptidase, c-rasH p21, rasGAP) or an extracellular antigen target (i.e., /3-amyloid protein 25 deposits in the brain of an Alzheimer's disease patient). Lipidized antibodies can traverse the blood-brain barrier and react with extracellular antigen targets that are generally inaccessible to immunoglobulins which circulate in the blood or lymphatic system. Lipidized antibodies can also react with 30 intracellular portions on transmembrane proteins, such as cytoplasmic tails of viral envelope glycoproteins or protein kinase domains of protooncogene proteins (c-src, c-abl), and thus inhibit production of infectious enveloped virus or kinase activity, respectively. 35 BRIEF DESCRIPTION OF THE DRAWINGS Figure l shows structural formulae representing WO 94/01131 255 043 PCT/ US93/06599 various lipoamines that can be used in the invention. The righthand column exemplifies branched-chain lipoamines and the lefthand column exemplifies straight-chain lipoamines. Figure 2 is a schematic representation of (1) a 5 glycosylated antibody comprising an immunoglobulin tetramer (two light chains associated with two heavy chains), and (2) a schematic representation of carbohydrate-linked lipidized immunoglobulins of the invention. For example but not limitation, branched-chain lipoamide substituents are shown 10 attached to partially oxidized carbohydrate sidechains of an immunoglobulin tetramer. Such carbohydrate sidechains may be located in the CH, VH, CL, and/or VL regions. Figure 3 shows the beneficial effect of a lipidized anti-Tat immunoglobulin on the in vitro survival of cells 15 infected with HIV-1 as compared to the lack of effect of the native (i.e., non-lipidized) anti-Tat immunoglobulin. Fig. 4 shows that the lipidized anti-Tat antibody significantly inhibited CAT activity (by approximately 75%), whereas native (unlipidized) anti-Tat antibody, lipidized 20 anti-gpl20 antibody, or rsCD4 were far less effective in inhibiting CAT activity in HLCD4-CAT cells. PETMLEP PEgQftlPTXQN Definitions 25 Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the 30 practice or testing of the present invention, the preferred methods and materials are described. For purposes of the present invention, the following terms are defined below. As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage (Immunology 35 - A Synthesis. 2nd Edition, E.S. Golub and D.R. Gren, Eds., Sinauer Associates, Sunderland, Massachusetts (1991), which is incorporated herein by reference). WO 94/01131 2 5 5 0 4 3 PCT/US93/06599 10 The term "corresponds to" is used herein to mean that a polynucleotide sequence is homoloqous (i.e., is identical, not strictly evolutionarily related) to all or a portion of a reference polynucleotide sequence, or that a 5 polypeptide sequence is identical to a reference polypeptide sequence. In contradistinction, the term "complementary to" is used herein to mean that the complementary sequence is homologous to all or a portion of a reference polynucleotide sequence. For illustration, the nucleotide sequence "TATAC" 10 corresponds to a reference sequence "TATAC" and is complementary to a reference sequence "GTATA". The terms "substantial similarity" or "substantial identity" as used herein denotes a characteristic of a polypeptide sequence or nucleic acid sequence, wherein the 15 polypeptide sequence has at least 50 percent sequence identity compared to a reference sequence, and the nucleic acid sequence has at least 70 percent sequence identity compared to a reference sequence. The percentage of sequence identity is calculated excluding small deletions or additions which total 20 less than 25 percent of the reference sequence. The reference sequence may be a subset of a larger sequence, such as a constant region domain of a constant region immunoglobulin gene; however, the reference sequence is at least 18 nucleotides long in the case of polynucleotides, and at least 25 6 amino residues long in the case of a polypeptide. The term "naturally-occurring" as used herein as applied to an object refers to the fact that an object can be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses) 30 that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory is naturally-occurring. A lipoprotein (e.g., a naturally-occuring isoprenylated or myristylated protein) that can be isolated from an organism that is found in nature and has not 35 been engineered by man is a naturally-occurring lipoprotein. "Glycosylation sites" refer to amino acid residues which are recognized by a eukaryotic cell as locations for the WO 94/01131 25 5 0 4 PCT/US93/06599 11 attachment of sugar residues. The amino acids where carbohydrate, such as oligosaccharide, is attached are typically asparagine (N-linkage), serine (O-linkage), and threonine (O-linkage) residues. The specific site of 5 attachment is typically signaled by a sequence of amino acids, referred to herein as a "glycosylation site sequence". The glycosylation site sequence for N-linked glycosylation is: -Asn-X-Ser- or -Asn-X-Thr-, where X may be any of the conventional amino acids, other than proline. The predominant 0 glycosylation site sequence for O-linked glycosylation is: -(Thr or Ser)-X-X-Pro-, where X is any conventional amino acid. The recognition sequence for glycosaminoglycans (a specific type of sulfated sugar) is -Ser-Gly-X-Gly-, where X is any conventional amino acid. The terms "N-linked" and "O-5 linked" refer to the chemical group that serves as the attachment site between the sugar molecule and the amino acid residue. N-linked sugars are attached through an amino group; O-linked sugars are attached through a hydroxyl group. However, not all glycosylation site sequences in a protein are 0 necessarily glycosylated; some proteins are secreted in both glycosylated and nonglycosylated forms, while others are fully glycosylated at one glycosylation site sequence but contain another glycosylation site sequence that is not glycosylated. Therefore, not all glycosylation site sequences that are 5 present in a polypeptide are necessarily glycosylation sites where sugar residues are actually attached. The initial N-glycosylation during biosynthesis inserts the "core carbohydrate" or "core oligosaccharide" (Proteins. Structures and Molecular Principles. (1984) Creighton (ed.), W.H. Freeman 10 and Company, New York, which is incorporated herein by reference). As used herein, "glycosylating cell" is a cell capable of glycosylating proteins, particularly eukaryotic cells capable of adding an N-linked "core oligosaccharide" 15 containing at least one mannose residue and/or capable of adding an o-linked sugar, to at least one glycosylation site sequence in at least one polypeptide expressed in said cell, WO 94/01131 2 5 5 0 4 3 PCT/US93/06599 12 particularly a secreted protein. Thus, a glycosylating cell contains at least one enzymatic activity that catalyzes the atU* shment of a sugar residue to a glycosylating site sequence in a protein or polypeptide, and the cell actually 5 glycosylates at least one expressed polypeptide. For example but not for limitation, mammalian cells are typically glycosylating cells. Other eukaryotic cells, such as insect cells and yeast, may be glycosylating cells. As used herein, the term "antibody" refers to a 10 protein consisting of one or more polypeptides substantially encoded by genes of the immunoglobulin superfamily (e.g., see The Immunoglobulin Gene Superfamilv. A.F. Williams and A.N. Barclay, in Immunoglobulin Genes. T. Honjo, F.W. Alt, and T.H. Rabbitts, eds., (1989) Academic Press: San Diego, CA, pp.361-15 387, which is incorporated herein by reference). For example, but not for limitation, an antibody may comprise part or all of a heavy chain and part or all of a light chain, or may comprise only part or all of a heavy chain. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma 20 (IgGlf IgG2, IgG3, IgG4), delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Full-length immunoglobulin "light chains" (about 25 Kd or 214 amino acids) are encoded by a variable region gene at the NH2-terminus (about 110 amino acids) and a kappa or lambda 25 constant region gene at the COOH - terminus. Full-length immunoglobulin "heavy chains" (about 50 Kd or 446 amino acids), are similarly encoded by a variable region gene (about 116 amino acids) and one of the other aforementioned constant region genes, e.g.. gamma (encoding about 330 amino acids). 30 Antibodies include, but are not limited to, the following: immunoglobulin fragments (e.g., Fab, F(ab)2), Fv) , single chain immunoglobulins, chimeric immunoglobulins, humanized antibodies, primatized antibodies, and various light chain-heavy chain combinations) . Antibodies can be produced in 35 glycosylating cells (e.g., human lymphocytes, hybridoma cells, yeast, etc.), in non-glycosylating cells (e.g., in E. coli), or synthesized by chemical methods or produced by in vitro WO 94/01131 255 043 PCT/US93/06599 13 translation systems using a polynucleotide template to direct translation. As used herein, a "lipidized antibody" is an antibody which has been modified by lipid derivatization (e.g., by covalent attachment of a lipoamine, such as glycyldioctadecylamide, dilauroylphosphatidylethanolamine, or dioctadecylamidoglycylspermidine) of one or more carbohydrate moieties attached to an immunoglobulin at a glycosylation site. Generally, the lipid substituent, such as a lipoamine, is covalently attached through a naturally-occurring carbohydrate moiety at a naturally-occurring glycosylation site. However, it is possible to produce immunoglobulins that have altered glycosylation site sequences (typically by site-directed mutagenesis of polynucleotides encoding immunoglobulin chains) and/or altered glycosylation patterns (e.g., by expression of immunoglobulin-encoding polynucleotides in glycosylating cells other than lymphocytes or in lymphocytes of other species). Lipid substituents can be attached to one or more naturally-occurring or non-naturally-occurring carbohydrate moiety on an immunoglobulin chain. When an antibody is produced by direct polypeptide synthesis or by biosynthesis in a non-glycosylating cell (e.g., a phage display library), it will generally be necessary to attach a carbohydrate substituent by chemical or enzymatic modification for subsequent lipidization (alternatively, the carbohydrate may be lipidized prior to attachment to the immunoglobulin). As used herein, a "lipidized protein" refers to a protein (including multimeric proteins, glycoproteins, and polypeptides of various sizes) that has been modified by attachment of lipid (»i.g., lipoamine), generally through a carbohydrate moiety. A lipidized protein is generated by derivatizing a protein such that the resultant lipidized protein is distinct from naturally-occurring lipid-linked proteins and lipoproteins. For proteins that are biologically active (e.g., enzymes, receptors, transcription factors), lipidization should not substantially destroy the biological 255 043 WO 94/01131 PCT/US93/06599 14 activity (e.g., at least about 15 percent of a native biological activity should be preserved in the lipidized protein). Lipidized peptidomimetics should retain at least about 25 to 95 percent of the pharmacologic activity of a 5 corresponding non-lipidized peptidomimetic. "Alkyl" refers to a fully saturated aliphatic group which may be cyclic, branched or straightchain. Alkyl groups include those exemplified by methyl, ethyl, cyclopropyl, cyclopropylmethyl, sec-butyl, heptyl, and dodecyl. All of the 10 above can either be unsubstituted or substituted with one or more non-interfering substitutents, e.g., halogen; Ca-C4 alkoxy; C^-C^ acyloxy; formyl; alkylenedioxy; benzyloxy; phenyl or benzyl, each optionally substituted with from 1 to 3 substituents selected from halogen, Cx-C4 alkoxy or 15 acyloxy. The term "non-interfering" characterizes the substituents as not adversely affecting any reactions to be performed in accordance with the process of this invention. If more than one alkyl group is present in a given molecule, each may be independently selected from "alkyl" unless 20 otherwise stated. "Alkylene" refers to a fully saturated divalent radical containing only carbon and hydrogen, and which may be a branched or straight chain radical. This term is further exemplified by radicals such as methylene, ethylene, 25 n-propylene, t-butylene, i-pentylene, n-heptylene, and the like. All of the above can either be unsubstituted or substituted with one or more non-interfering sustituents, e.g., halogen; Cx-C4 alkoxy; 01-CA acyloxy; formyl; alkylenedioxy; benzyloxy; phenyl or benzyl, each optionally 30 substituted with from 1 to 3 substituents selected from halogen, Ca-C4 alkoxy or C^-C4 acyloxy. The term "non-interfering" characterizes the substituents as not adversely affecting any reactions to be performed in accordance with the process of this invention. If more than one alkylene group is 35 present in a given molecule, each may be independently selected from "alkylene" unless otherwise stated. "Aryl", denoted by Ar, includes monocyclic or 2 5 5 0 4 3 PCT/US93/06599 condensed carbocyclic aromatic groups having from 6 to 20 carbon atoms. Aryl groups include those exemplified by phenyl and naphthyl. These groups may be substituted with one or more non-interfering substituents, e.g., those selected from 5 lower alkyl; lower alkenyl; lower alkynyl; lower alkoxy; lower alkylthio; lower alkylsulfinyl; lower alkylsulfonyl, dialkylamine; halogen; hydroxy; phenyl; phenyloxy; benzyl; benzoyl; and nitro. Each substituent may be optionally substituted with additional non-interfering substituents. 10 "Amino" refers to the group -NH2. "Alkylcarbonyl" refers to the group -(CHR^-CO-wherein Rx is further designated the a-position. Rx may be hydrogen, alkyl, or an amino group. Preferably is an amino group. 15 Description of the Preferred Embodiments In accordance with the present invention, novel methods for chemically modifying proteins, such as antibodies, to facilitate passage across capillary barriers and into cells 20 are provided. In general, the methods include the covalent attachment of at least one non-interfering lipid substituent (e.g., glycyldioctadecylamide, glycyldiheptadecylamide, glycyldihexadecylamide, dilauroylphosphatidylethanolamine, and glycyldioctadecadienoylamide) to a reactive site in the 25 protein molecule (e.g., a periodate-oxidized carbohydrate moiety). Various non-interfering lipid substituents may be attached to proteins to produce lipidized proteins, such as lipidized antibodies of the invention. For example but not for limitation, the following examples of lipids may be 30 conjugated to a protein of interest to yield a lipidized protein: lipoamines, lipopolyamines, and fatty acids (e.g., stearic acid, oleic acid, and others). Generally, the lipid will be attached by a covalent linkage to a carbohydrate linked to the protein (e.g., a carbohydrate side chain of a 35 glycoprotein). Naturally-occurring carbohydrate side-chains are preferably used for linkage to a lipoamine, although novel glycosylation sites may be engineered into a polypeptide by WO 94/01131 WO 94/01131 2 5 5 0 A 3 PCT/US93/06599 16 genetic manipulation of an encoding polynucleotide, and expression of the encoding polynucleotide in a glycosylating cell to produce a glycosylated polypeptide. Glycosylated proteins can be lipidized to enhance transvascular transport, organ uptake, and intracellular localization of the lipidized protein, including intranuclear localization. Generally, a glycosylated polypeptide, such as an antibody, is chemically oxidized with an oxidizing agent (e.g., periodate) to yield pendant carboxy1 and/or aldehyde groups, and reacted with a lipoamine to form a covalcmt (amide or imide, respectively) bond linking the lipoamine to the protein. Typically, the oxidation of the carbohydrace side-chain is a partial oxidation producing at least one reactive carboxyl or aldehyde group, although generally chemical oxidation methods will produce some molecules that are partially oxidized and others that are either unoxidized or completely oxidized. However, in order to be lipidized by reaction with a lipoamine, the glycoprotein must be oxidized to produce at least one pendant aldehyde group that can react with a lipoamine, although it may be possible to produce lipidized proteins through linkage to pendant carboxyl groups as well. A pendant carboxyl or aldehyde group of an oxidized glycoprotein is a carboxyl or aldehyde group having a carbonyl carbon derived from an oxidized oligosaccharide and which is covalently attached to the protein, either directly or through a spacer (e.g., an unoxidized portion of a N- or O-linked carbohydrate side-chain). Preferably, N-linked and O-linked carbohydrate chains are incompletely oxidized to generate a multiplicity of reactive aldehyde and carboxyl groups at each glycosylation position for subsequent reaction with lipoamines. Most usually, glycoproteins having one or more complex N-linked oligosaccharides, such as those having a branched (mannose^f/S-N-acetylglucosamino) core, are partially oxidized by limited reaction with a suitable oxidant, generally periodate. Linked oligosaccharides containing N-acetylglucosamine (NAG), mannose, galactose, fucose (6-deoxygalactose), N-acetylneuraminic acid (sialic acid), WO 94/01131 255043 PCT / US93/06599 17 glucose, N-acetylmuramic acid, N-acetylgalactosamine, xylose, or combinations of these monosaccharide units can be oxidized and reacted with lipoamines to produce lipidized proteins, more specifically carbohydrate-linked lipidized proteins. 5 Glycoproteins containing linked oligosaccharides with monosaccharide units other than those specifically listed above for exemplification, including non-naturally occurring monosaccharides, can also be oxidized and covalently linked to a lipoamine to form a lipidized protein. 10 Lipoamines are molecules having at least one acyl group and at least one free amine (i.e., a primary or secondary amine). It is believed that the invention can also be practiced with lipoamines that have tertiary amines which comprise at least one substituent that can be displaced by 15 reaction with an oxidized carbohydrate. Examples of lipoamines having a primary amine are shown in Fig. 1. For example, the invention can produce lipidized proteins by reacting a glycoprotein with a straight-chain lipoamine of the 20 formula: NH2-R-(CH2)n-CH3 where R is: a disubstituted alkyl (alkylene), preferably methylene (-CH2-); a 1,4-disubstituted cyclohexyl; 25 a disubstituted aryl (arylene); preferably a 1,4-disubstituted phenyl (phenylene) ; an amido group of the formula -(CHR^-CO-NH- wherein Ra is hydrogen or an amino group; alkylcarbonyl, preferably a-amino substituted alkylcarbonyl; or a phosphate diester, preferably of the formula -CH2-0-P02-0-. n is an 30 integer which is typically 1 to 50, preferably about 5 to 30, more preferably about 10 to 25, and most usually about 15 to 20. In general, n is selected at the discretion of the practitioner according to the following guideline: when the molecule to be lipidized is large (i.e., a protein of more 35 than about 10 kD) it is preferred than n is at least about 8 to 12 or more to increase the hydrophobicity of the resulting lipidized protein; when the molecule to be lipidized is small WO 94/01131 255 043 PCT/ US93/06599 10 18 (e.g. , an oligopeptide) n can typically be in the range 2 to 18, but may be larger if additional hydrophobicity of the lipidized molecule is desired. The invention can also be practiced with branched-chain lipoamines, which, for example, can include lipoamines of the formula: NH2-Rj-(CH2)n-CH3 (CH2)m CH, where r1 is: a trisubstituted alkyl, preferably -15 ch2-ch< or 1,2,4-trisubstituted cyclohexyl; a trisubstituted aryl, preferably 1,2,4-trisubstituted phenyl; an amido group of the formula - (chr1) -co-n< wherein rx is hydrogen or an amino group; an imino group of the formula -chr2-nh-ch< wherein r2 is hydrogen or an amino group or an imino group of the formula -20 ch2-N<; or a phosphate diester, preferably of the formula -ch2-ch2-0-p02-0-ch2-ch(c02-)2. m and n are selected independently and are integers which are typically l to 50, preferably about 5 to 30, more preferably about 10 to 25, and roost usually about 15 to 20. In general, n is selected at the discretion 25 of the practitioner according to the following guideline: when the molecule to be lipidized is large (i.e., a protein of more than about 10 kD) it is preferred than m and/or n is at least about 8 to 12 or more to increase the hydrophobicity of the resulting lipidized protein; when the molecule to be lipidized 30 is small (e.g., an oligopeptide) n can typically be in the range 2 to 18, but may be larger if additional hydrophobicity of the lipidized molecule is desired. Essentially any glycoprotein can be lipidized according to the methods of the invention by reacting a 35 lipoamine with an oxidized carbohydrate side-chain. Fig. 2 shows schematically a glycosylated antibody and a carbohydrate-linked lipidized antibody of the invention, respectively. Non-glycosylated proteins may be conjugated to a lipid by linkage through a suitable crosslinking agent 40 (e.g., by carbodiimide linkage chemistry). WO 94/01131 255 043 PCT/US93/06599 19 In accordance with the present invention, novel lipidized antibodies capable of specifically binding to predetermined intracellular epitopes with strong affinity are provided. These antibodies readily enter the intracellular 5 compartment and have binding affinities of at least about 1 x 106 M"1, preferably 1 x 107 M"1 to 1 x 10® M"*1, more preferably at least about 1 x 109 M"1 or stronger. The lipidized antibodies typically have a lipid substituent attached to a naturally-occurring carbohydrate side chain on a donor 10 immunoglobulin chain, which composes an antibody specifically reactive with an intracellular, transmembrane, or extracellular epitope. Since carbohydrates are located on the Fc portion of immunoglobulins, chemical modification of the carbohydrate residues by lipidization would be unlikely to 15 produce a substantial loss of affinity of the antibodies for their antigens (Rodwell et al. (1986) Proc. Natl. Acad. Sci. (U.S.A.1 83: 2632). The lipidized antibodies generally retain substantial affinity for their antigen, and the avidity can be readily measured by any of several antibody-antigen binding 20 assays known in the art. The antibodies can be produced economically in large quantities and find use, for example, in the treatment of various human disorders by a variety of techniques. One form of immunoglobulin constitutes the basic 25 structural unit of an antibody. This form is a tetramer and consists of two identical pairs of immunoglobulin chains, each pair having one light and one heavy chain. In each pair, the light and heavy chain variable regions are together responsible for binding to an antigen, and the constant 30 regions are responsible for the antibody effector functions. In addition to antibodies, immunoglobulins may exist in a variety of other forms including, for example, Fv, Fab, and (Fab,)2/ as well as bifunctional hybrid antibodies, fusion proteins (e.g., bacteriophage display libraries), and other 35 forms (e.g.. Lanzavecchia et al., Eur. J. Immunol. 17. 105 (1987)) and in single chains (e.g.. Huston gt al.. Proc. Natl. Acad. Sci. U.S.A.. 35,, 5879-5883 (1988) and Bird §& al. . 255 043 WO 94/01131 PCT/US93/06599 m 20 Science. 242. 423-426 (1988)). (See. generally, Hood fi£ al*., "Immunology", Benjamin, N.Y., 2nd ed. (1984), and Hunkapiller and Hood, Nature. 323. 15-16 (1986)). Antibodies can be produced in glycosylating cells 5 (e.g., human lymphocytes, hybridoma cells, yeast, etc.), in non-glycosylating cells (e.g., in E. coli), or synthesized by chemical methods or produced by ill vitro translation systems using a polynucleotide template to direct translation. One source of hybridoma cell lines and imxnunoglobulin-encoding 10 polynucleotides is American Type Culture Collection, Rockville, MD. Methods for expression of heterologous proteins in recombinant hosts, chemical synthesis of polypeptides, and jjQ vitro translation are well known in the art and are described further in Maniatis et al., Molecular 15 Cloning; A Laboratory Manual (1989), 2nd Ed., Cold Spring Harbor, N.Y.; Berger and Kimmel, Methods in Enzvmologv. Volume 152. Guide to Molecular Cloning Technioues (1987), Academic Press, Inc., San Diego, CA; Merrifield, J. (1969) J. Am. Chem. Soc. 21: 501; Chaiken I.M. (1981) CRC Crit. Rev. Biochem. H: 20 255; Kaisier et al. (1989) Science 243: 187; Merrifield, B. (1986) Science 232: 342; Kent, S.B.H. (1988) Ann. Rev. Biochem. 52: 957; and Offord, R.E. (1980) Semisynthetic Proteins. Wiley Publishing, which are incorporated herein by reference). Antibodies that are produced in non-glycosylating 25 cells can be conjugated to a lipid by use of a bifunctional crosslinking agent or preferably post-translationally glycosylated in a glycosylation system such as purified canine pancreatic microsomes (Mueckler and Lodish (1986) Cell M: 629 and Walter, P. (1983) Meth. Enzvmol. 96: 84, which are 30 incorporated herein by reference). Alternatively, polynucleotides that encode antibodies may be isolated from screened prokaryotic expression libraries, such as combinatorial antibody fragment display libraries, and subsequently expressed in glycosylating cells to produce 35 glycosylated antibodies. According to these methods, glycosylated antibodies may be obtained, having naturally-occurring and/or non-naturally-occurring glycosylation WO 94/01131 255043 PCT/US93/06599 21 patterns. Such glycosylated antibodies can be lipidized according to the methods of the invention. Glycosylation of immunoglobulins has been shown to have significant effects on their effector functions, 5 structural stability, and rate of secretion from antibody-producing cells (Leatherbarrow et al., Mol. Immunol. £2.: 407 (1985)). The carbohydrate groups responsible for these properties are generally attached to the constant (C) regions of the antibodies. For example, glycosylation of IgG at 10 asparagine 297 in the CH2 domain is required for full capacity of IgG to activate the classical pathway of complement-dependent cytolysis (Tao and Morrison, J. Immunol. 143: 2595 (1989)). Glycosylation of IgM at asparagine 402 in the CH3 domain is necessary for proper assembly and cytolytic activity 15 of the antibody (Muraoka and Shulman, J. Immunol. 142; 695 (1989)). Removal of glycosylation sites as positions 162 and 419 in the CH1 and CH3 domains of an IgA antibody lead to intracellular degradation and at least 90% inhibition of secretion (Taylor and Nail, Mol. Cell. Biol. j£: 4197 (1988)). 20 Glycosylation of immunoglobulins in the variable (V) region has also been observed. Sox and Hood, Proc. Natl. Acad. Sci. USA 66: 975 (1970), reported that about 20% of human antibodies are glycosylated in the V region. Glycosylation of the V domain is believed to arise from 25 fortuitous occurrences of the N-linked glycosylation signal Asn-Xaa-Ser/Thr in the V region sequence and has not been recognized in the art as playing an important role in immunoglobulin function. Therefore, it is generally preferred that 30 lipidization is performed on antibodies having naturally- occurring glycosylation patterns. If glycosylation sites are engineered into an antibody, it is preferred that novel glycosylation site be introduced in a constant region or variable region framework region, which are less likely to 35 adversely affect the antigen binding activity of the antibody. It is generally most preferred that novel glycosylation sites which are engineered into an antibody are placed in a constant 255 043 PCT / US93/06599 region. Alternatively, polypeptide fragments comprising only a portion of a primary antibody structure and having a carbohydrate side chain that may be derivatized with a lipid 5 substituent (e.g., lipoamine) can be produced, which fragments possess one or more immunoglobulin activities (e.g., antigen binding activity). These polypeptide fragments may be produced by proteolytic cleavage of intact antibodies by methods well known in the art, or by site-directed mutagenesis 10 at the desired locations in expression vectors containing sequences encoding immunoglobulin proteins, such as after CHX to produce Fab fragments or after the hinge region to produce (Fab')2 fragments. Single chain antibodies may be produced by joining VL and VH with a DNA linker (see. Huston et al., op. 15 cit., and Bird et al., op. cit.). Also because like many genes, the inununoglobulin-related genes contain separate functional regions, each having one or more distinct biological activities, the genes may be fused to functional regions from other genes having novel properties. Nucleic 20 acid sequences for producing immunoglobulins for the present invention are capable of ultimately expressing the desired antibodies and can be formed from a variety of different polynucleotides (genomic or cDNA, RNA, synthetic oligonucleotides, etc.) and components (e.g., V, J, D, and C 25 regions) , as well as by a variety of different techniques. Joining appropriate synthetic and genomic sequences is presently the most common method of production, but cDNA sequences may also be utilized (see. European Patent Publication No. 0239400 and L. Reichmann et al.. Nature. 332. 30 323-327 (1988)). Immunoglobulins and/or DNA sequences encoding immunoglobulin chains may be obtained, for example, by hybridoma clones which can be produced according to methods known in the art (Kohler and Milstein (1976) Eur. J. Immunol. 35 £: 511, incorporated herein by reference) or can be obtained from several sources ("ATCC Catalog of Cell Lines and Hybridomas", American Type Culture Collection, Rockville, MD, WO 94/01131 22 255 043 WO 94/01131 PCT / US93/06599 23 which is incorporated herein by reference). DNA sequences encoding immunoglobulin chains can be obtained by conventional cloning methods known in the art and described in various publications, for example, Maniatis et al., Molecular Cloning: 5 A Laboratory Manual. 2nd Ed., (1989), Cold Spring Harbor, N.Y. and Berger and Kimmel, Methods in Enzvmoloov. Volume 152. Guide to Molecular Cloning Technigues (1987), Academic Press, Inc., San Diego, CA, which are incorporated herein by reference. 10 As stated previously, the DNA sequences will be expressed in hosts, typically glycosylating cells, after the sequences have been operably linked to (i.e., positioned to ensure the functioning of) an expression control sequence. These expression vectors are typically replicable in the host 15 organisms either as episomes or as an integral part of the host chromosomal DNA. Commonly, expression vectors will contain selection markers, e.g., tetracycline-resistance or G418-resistance, to permit detection of those cells transformed with the desired DNA sequences fsee. e.g., U.S. 20 Patent 4,704,362). E. coll is one prokaryotic host useful particularly for cloning.the DNA sequences of the present invention. Other microbial hosts suitable for use include bacilli, such as Bacillus subtills, and other Enterobacteriaceae, such as 25 Salmonella, Serratia, and various Pseudomonas species. In these prokaryotic hosts, one can also make expression vectors, which will typically contain expression control sequences compatible with the host cell (e.g., an origin of replication). In addition, any number of a variety of well-30 known promoters will be present, such as the lactose promoter system, a tryptophan (trp) promoter system, a /3-galactosidase promoter system, or a promoter system from phage lambda. The promoters will typically control expression, optionally with an operator sequence, and have ribosome binding site sequences 35 and the like, for initiating and completing transcription and translation. Proteins, such as antibodies, that are expressed in non-glycosylating cells can be post-translationally WO 94/01131 255 043 PCT/ US93/06599 24 glycosylated in a glycosylation system (Mueckler and Lodish, op.cit.. which is incorporated herein by reference. Other microbes, such as yeast, may also be used for expression. Saccharomyves is a preferred host glycosylating 5 cell, with suitable vectors having expression control sequences, such as promoters, including 3-phosphoglycerate kinase or other glycolytic enzymes, and an origin of replication, termination sequences and the like as desired. In addition to microorganisms, mammalian tissue cell 10 culture may also be used to express and produce the polypeptides of the present invention (Bee. Winnacker, "From Genes to Clones," VCH Publishers, N.Y., N.Y. (1987)). Eukaryotic cells are actually preferred, because a number of suitable host cell lines capable of secreting intact 15 immunoglobulins have been developed in the art, and include the CHO cell lines, various COS cell lines, HeLa cells, preferably myeloma cell lines, etc, and transformed B-cells or hybridomas. Expression vectors for these cells can include expression control sequences, such as an origin of 20 replication, a promoter, an enhancer (Queen • Immunol. Rev.. 89. 49-68 (1986)), and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences. Preferred expression control sequences are 25 promoters derived from immunoglobulin genes, SV40, Adenovirus, cytomegalovirus, Bovine Papilloma Virus, and the like. The vectors containing the DNA segments of interest (e.g., the heavy and light chain encoding sequences and expression control sequences) can be transferred into the host 30 cell by well-known methods, which vary depending on the type of cellular host. For example, calcium chloride transfection is commonly utilized for prokaryotic cells, whereas calcium phosphate treatment or electroporation may be used for other cellular hosts. (See, generally, Maniatis al.. Molecular 35 Cloning: A Laboratory Manual, Cold Spring Harbor Press, (1982).) Once expressed, the whole antibodies, their dimers, Z D 0 u 4 3 WO 94/01131 PCT/US93/06599 25 individual light and heavy chains, or other immunoglobulin forms of the present invention, can be purified according to standard procedures of the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel 5 electrophoresis and the like (see, generally, R. Scopes, "Protein Purification", Springer-Verlag, N.Y. (1982)). Substantially pure immunoglobulins of at least about 90 to 95% homogeneity are preferred, and 98 to 99% or more homogeneity most preferred, for pharmaceutical uses. Once purified, 10 partially or to homogeneity as desired, the polypeptides may then be used therapeutically (including extracorporeally) or in developing and performing assay procedures, immunofluorescent stainings, and the like. (See. generally, Immunological Methods. Vols. I and II, Lefkovits and Pernis, 15 eds., Academic Press, New York, N.Y. (1979 and 1981)). In the methods of the invention, intact immunoglobulins or their binding fragments, such as Fab, are preferably used. Typically, lipidized antibodies will be of the human IgM or IgG isotypes, but other mammalian constant 20 regions may be utilized as desired. Lipidized antibodies of the IgA, IgG, IgM, IgE, IgD classes may be produced. Preferably, the lipidized antibodies of the invention are human, murine, bovine, equine, porcine, or non-human primate antibodies, more preferably human or murine antibodies. The 25 invention can be used to produce lipidized antibodies of various types, including but not limited to: chimeric antibodies, humanized antibodies, primatized antibodies, Fv fragments, toxin-antibody conjugates, isotope-antibody conjugates, and imaging agent-antibody conjugates. For in 30 vivo imaging, lipidized antibodies are suitably labeled with a diagnostic label, administered to the patient, and their location determined at various times following administration. Various methods of labeling antibodies with diagnostic reporters (e.g., with Tc", other radioligands, radiocontrast 35 agents or radio-opaque dye) are known in the art. Proteins and oligopeptides (i.e., polypeptides comprising from 2 to about 50 amino acid residues attached in WO 94/01131 * o d u q $ PCT/US93/06599 26 peptidyl linkage) other than immunoglobulins can be lipidized according to the methods the invention. Naturally-occurring glycoproteins (e.g., 7-glutamyltranspeptidase, thrombomodulin, glucose transporter proteins) are preferred substrates for 5 lipidization through carbohydrate linkage, although substantially any polypeptide can be lipidized by covalent attachment through a crosslinking agent (e.g., N-hydroxysuccimide) to a suitable amino acid side chain. In alternate embodiments of the invention, at least one lipid 10 substituent (e.g., lipoamine) is covalently attached to a non-carbohydrate moiety on a protein or polypeptide (e.g., by formation of an amide linkage with a Asp or Glu residue side-chain carboxyl substituent or a thioester linkage with a Cys residue). Also, a fatty acid can be linked to an Arg or Lys 15 residue by the side-chain amine substituents. Examples of non-glycosylated proteins which may be lipidized for enhancing transvascular and intracellular transport include, but are not limited to, the following proteins: c-fos, c-myc, c-src, NF-AT, and HMG CoA reductase. Naturally-occurring lipoproteins, 20 such as native proteins which undergo physiological farnesylation, geranylgeranylation, and palmitylation are natural products and are not defined herein as "lipidized proteins". The lipidized antibodies and pharmaceutical 25 compositions thereof are particularly useful for parenteral administration, i.e., subcutaneously, intramuscularly or intravenously. The compositions for parenteral administration will commonly comprise a solution of the immunoglobulin or a cocktail thereof dissolved in an acceptable carrier, 30 preferably an aqueous carrier. A variety of aqueous carriers can be used, e.g., water, buffered water, 0.4% saline, 0.3% glycine and the like. These solutions are sterile and generally free of particulate matter. These compositions may be sterilized by conventional, well known sterilization 35 techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering 255 043 WO 94/01131 PCT/US93/06599 27 agents, toxicity adjusting agents and the like, for example sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, human albumin, etc. The concentration of antibody in these formulations can vary 5 widely, i.e., from less than about 0.5%, usually at or at least about 1% to as much as 15 or 20% by weight and will be selected primarily based on fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected. 10 Thus, a typical pharmaceutical composition for injection could be made up to contain 1 ml sterile buffered water, and 1-10 mgs of lipidized immunoglobulin. A typical composition for intravenous infusion could be made up to contain 250 ml of sterile Ringer's solution, and 150 mg of 15 antibody. Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art and are described in more detail in, for example, Remington's Pharmaceutical Science. 15th ed., Mack Publishing Company, Easton, Pennsylvania (1980), which is 20 incorporated herein by reference. The lipidized proteins and antibodies of this invention can be frozen or lyophilized for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with conventional 25 immune globulins and art-known lyophilization and reconsti-tution techniques can be employed. It will be appreciated by those skilled in the art that lyophilization and recon-stitution can lead to varying degrees of activity loss (e.g., with conventional immune globulins, IgM antibodies tend to 30 have greater activity loss than IgG antibodies) and that use levels may have to be adjusted to compensate. The compositions containing the present lipidized proteins (e.g., antibodies) or a cocktail thereof can be administered for prophylactic and/or therapeutic treatments. 35 In therapeutic application, compositions are administered to a patient in an amount sufficient to cure or at least partially arrest the disease ard its complications. An amount adequate WO 94/01131 255 043 PCT/US93/06599 28 to accomplish this is defined as a "therapeutically effective dose." Amounts effective for this use will depend upon the severity of the infection and the general state of the patient's own immune system, but generally range from about 1 5 to about 200 mg of antibody per dose, with dosages of from 5 to 25 mg being more commonly used. It must be kept in mind that the materials of this invention may generally be employed in serious disease states, that is life-threatening or potentially life-threatening situations. 10 In prophylactic applications, compositions containing the present immunoglobulins or a cocktail thereof are administered to a patient not already in a disease state to enhance the patient's resistance. Such an amount is defined to be a "prophylactically effective dose." In this 15 use, the precise amounts again depend upon the patient's state of health and general level of immunity, but generally range from 0.1 to 25 mg per dose. Single or multiple administrations of the compositions can be carried out with dose levels and pattern 20 being selected by the treating physician. In any event, the pharmaceutical formulations should provide a quantity of the lipidized proteins and/or lipidized antibody(ies) of this invention sufficient to effectively treat the patient. For diagnostic purposes, the lipidized antibodies 25 may either be labeled or unlabeled. Unlabeled antibodies can be used in combination with other labeled antibodies (second antibodies) that are reactive with the lipidized antibody, such as antibodies specific for human immunoglobulin constant regions. Alternatively, the lipidized antibodies can be 30 directly labeled. A wide variety of labels may be employed, such as radionuclides, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, ligands (particularly haptens), radiocontrast agents, metal chelates, etc. Numerous types of diagnostic imaging applications are available and are well 35 known to those skilled in the art. For example, but not for limitation, an antibody that binds to a tumor antigen (e.g., anti-CEA antibodies) may be lipidized and conjugated to a WO 94/01131 255 043 PCT/US93/06599 29 radiocontrast agent or magnetic imaging material, injected into a human patient, and detected so as to localize the position of a tumor or metastatic lesion. The lipidized immunoglobulins of the present 5 invention can be used for diagnosis and therapy. By way of illustration and not limitation, they can be used to treat cancer, autoimmune diseases, or viral infections. For treatment of cancer, the antibodies will typically bind to an antigen expressed preferentially in certain cancer cells, such 10 as c-mvc gene product and others well known to those skilled in the art. Preferably, the lipidized antibody will bind to a mutant protein, such as a c-ras oncogene product having a pathogenic (e.g., neoplastic) sequence, such as a substitution at position 12, 13, 59, or 61 of the protein (e.g., a Ser at 15 position 12 of p21ras). For treatment of autoimmune disease, the antibodies will typically bind to an critical regulatory protein expressed primarily in activated T-cells, such as NF-AT, and many other intracellular proteins well known to those skilled in the art (e.g., see Fundamental Immunology. 2nd ed., 20 W.E. Paul, ed., Raven Press: New York, NY, which is incorporated herein by reference). For treatment of viral infections, the antibodies will typically bind to a protein expressed in cells infected by a particular virus such as the various viral encoded polymerases and HIV-1 Tat, and many 25 other viral proteins well known to those skilled in the art (e.g., see Virology. 2nd ed., B.N. Fields et al., eds., (1990), Raven Press: New York, NY, which is incorporated herein by reference). Kits can also be supplied for use with the subject 30 lipidized antibodies in the protection against or detection of a cellular activity or for the presence of a selected cell intracellular protein or the diagnosis of disease. Thus, the subject composition of the present invention may be provided, usually in a lyophilized form in a container, either alone or 35 in conjunction with additional antibodies specific for the desired cell type. The lipidized antibodies, which may be conjugated to a label or toxin, or unconjugated, are included WO 94/01131 255 043 PCT/ US93/06599 30 in the kits with buffers, such as Tris, phosphate, carbonate, etc., stabilizers, biocides, inert proteins, e.g., serum albumin, or the like, and a set of instructions for use. Generally, these materials will be present in less than about 5 5% wt. based on the amount of active antibody, and usually present in total amount of at least about 0.001% wt. based again on the antibody concentration. Frequently, it will be desirable to include an inert extender or excipient to dilute the active ingredients, where the excipient may be present in 10 from about 1 to 99% wt. of the total composition. Where a second antibody capable of binding to the lipidized antibody is employed in an assay, this will usually be present in a separate vial. The second antibody is typically conjugated to a label and formulated in an analogous manner with the 15 antibody formulations described above, as well as typically also being lipidized itself. The lipidized antibodies of the present invention are also suited for use in improved diagnostic methods and protein purification methods. For example, many intracellular 20 proteins are unstable (e.g., short half-life, susceptible to proteolysis) or prone to aggregation (e.g., 0-amyloid protein) making purification and/or diagnostic detection difficult. Lipidized antibodies are able to penetrate living cells and bind to specific intracellular target antigens; such antibody-25 antigen binding may stabilize the target antigen and block enzymes involved in degradation of the target antigen (e.g., proteases, ubiquitin-conjugating enzymes, glycosidases) facilitating detection and/or purification of the target antigen. 30 in one variation of the invention, a lipidized antibody which specifically binds to an intracellular target antigen is contacted with live cells comprising the intracellular target antigen under physiological conditions (e.g., cell culture conditions, somatic conditions) and 35 incubated for a suitable binding period (e.g., from about 10 minutes to several hours). The lipidized antibody specifically binds to the target antigen forming an antigen- WO 94/01131 2 5^ 043 PCT/U' V06599 31 antibody complex which is leas susceptible to degradation and/or aggregation that is the target antigen itself. Typically, the cells are then fixed and permeabilized and the antigen-antibody complex, comprising the target antigen bound 5 to the lipidized antibody, is detected, usually with a labeled secondary antibody that specifically binds the the lipidized antibody. Examples of preferred labels attached to the secondary antibody are: FITC, rhodamine, horseradish peroxidase conjugates, alkaline phosphatase conjugates, |9-10 galctosidase conjugates, biotinyl moieties, radioisotopes, and the like. In some embodiments, the secondary antibody may be lipidized and the fixation and/or permeabilization steps may be omitted and replaced with substantial washing of the cell sample to remove non-specific staining. It may also be 15 possible to use a lipidized, labeled primary antibody directly and omit the second antibody. Labelled protein A may also be substituted for a secondary antibody for the detection of the primary (lipidized) antibody. Lipidized antibodies may also be used for 20 intracellular therapy, such as for binding to a predetermined intracellular target antigen and modifying a biochemical property of the target antigen. For example, multi-subunit proteins, such as heteromultimeric proteins (e.g., transcription factors, G-proteins) or homodimeric proteins 25 (e.g., polymerized tubulin) may possess a biochemical activity (e.g., GTPase activity) or other activity that requires intermolecular interaction(s) that may be blocked by a lipidized antibody that specifically binds to one or more subunits and prevents functional interaction of the subunits. 30 For example, a lipidized anti-Fos antibody which binds to a portion of Fos (e.g., leucine zipper) required for binding to Jun to form a transcriptionally active AP-1 transcription factor (Fos/Jun heterodimer) may block formation of functional AP-i and inhibit AP-l-mediated gene transcription. Also for 35 example, a lipidized anti-ras antibody may bind to an epitope of ras which is required for its proper signal transduction function (e.g., a GTP/GDP-binding site, a portion of ras that WO 94/01131 » 32 binds an accessory protein such as GAP, or the like), therebymodifying the activity of intracellular rats in living cells. The following examples are offered by way of 5 illustration, not by way of limitation. experimental examples EXAMPLE 1 Preparation of a Lipidized Bovine IaG 10 Glycyldioctadecylamide was obtained by linking a glycine residue to dioctadecylamine according to the method described by Behr et al. (1989) Proc. Natl. Acad. Sci. (U.S.A.\ ££: 6982, which is incorporated herein by reference. Benzyloxycarbonyl-glycyl-p-nitrophenol at l equivalent and 15 triethylaxnine at 1.1 equivalents in CH2C12 are reacted for 5 hours, followed by addition of H2, 10% Pd/C in CH2Cl2/EtOH and reaction for 1 hour. Two mg of bovine IgG (Sigma) were dissolved in 400 Ml of 300 mM NaHC03 in a 1.5 ml Eppendorf vial. Fifty Ml of a 20 freshly prepared NaI04 solution (42 mg/ml in H20) were added and the vial was wrapped in aluminum foil and gently shaken for 90 min. at room temperature. The reaction medium was then loaded on a PD-10 column (Pharmacia) previously equilibrated with 10 mM Na2C03 (fraction 1), and the column was eluted with 25 500 Ml fractions. Fraction number 7 (between 3 ml and 3.5 ml) contained approximately 1.6 mg of bovine IgG as measured using the Bradford protein assay. A solution of glycyldioctadecylamide in DMSO was prepared (5 mg of the lipid into 1 ml of DMSO, vigorously 30 vortexed for several minutes). Under those conditions the lipid was not fully dissolved. Fifty Ml of this solution were taken carefully (and did not contain any undissolved lipid) and were added to 350 Ml of fraction 7 obtained as described above, in an Eppendorf vial. The vial was wrapped in aluminum 35 foil, and the mixture was gently shaken for 20 h at room temperature. One hundred m1 of a solution of NaBH4 (10 mg/ml in 3 25 5 0 43 PCT/US93/06599 H20) vera then added. After one hour, 40 /ul of a solution of ethanolamine (15 Ml in 1 ml H20) were added. After an additional l h, the reaction mixture was loaded on a PD-10 column previously equilibrated in 100 mM HEPES buffer, pH 8.5. 5 The fraction containing the lipidized IgG (between 3 and 3.5 ml) was oolleoted and stored on ice. Labelling with 14C-acetlc anhydride 14c-acetic anhydride (500 nd, Amersham) in benzene 10 (10x10® cpm/Ml) was used. Two 5 Ml aliquots were added to the 500 m1 fraction containing the lipidized IgG at 10 min interval in an Eppendorf vial. The reaction was left on ice. A 500 Ml solution of native IgG (800 ng in 100 mM HEPES, pH 8.5) was treated the same way. 15 After 30 min. the vials were warmed to 20 to 25*C, the 14C-labelled IgGs were separated from free 14C-acetate on a PD-10 column equilibrated with PBS. Radioactivity incorporated was of approximately lOxlO6 cpm for 500 nq. 20 Organ wtata Bodies Male swiss albinos mice (20g) were used. One hundred Ml of 14C-labeled lipidized IgG or 14C-labeled control IgG in PBS (approximately 400,000 dpm each) were administered intravenously by tail vein injection. Mice were killed after 25 30 min or 3 h, their blood collected in EDTA-containing tubes, and their brain (minus cerebellum and brainstem), spleen, one kidney and one liver lobe were dissected. Organs were homogenized in 1 ml 10 mM Tris buffer, pH 7.4, and 500 Ml aliquots were counted in a Beckman scintillation counter. 30 Protein concentration in these homogenates was determined by the Bradford assay (Coomassie blue). The blood was centrifuged and 20 Ml fractions of the plasma were counted. Table I shows the uptake of 14C in the brain, liver, spleen and kidney, expressed as the ration of radioactivity in 1 M9 35 protein of the organs divided by the radioactivity in 1 Ml plasma (data expressed as m1/M9 protein). WO 94/01131 WO 94/01131 255 043 PCT/US93/06599 34 TABLE I Organ 30 minutes control Lipidized 3 howre control Lipidized Brain Kidney Liver Spleen .20 ± .03 1.46 ± .31 1.26 ± .26 1.08 ± .27 .32 ± .08 9.50 ± 2.19 4.95 1 .82 4.54 ± .76 .94 ± .05 1.17 ± .04 .66 ± .04 1.13 ± .03 1.75 ± .09 3.54 ± .22 7.59 ± .27 12.0 ± 2.15 10 Control groups of 4 and 6 mice at 30 min and 3 hr, respectively. Groups receiving the lipidized IgG were of 6 mice at both time points. Data are means ± s.e.m. EXAMPLE 2 15 Inhibition of HIV-1 Cytotoxicity with Lipidized Anti-Tat Antibody A monoclonal antibody which specifically binds the Tat protein of HIV-1 was lipidized according to the method described in Example l, supra. involving periodate oxidation 20 of carbohydrate on the antibody, followed by covalent attachment of glycyldioctadecylamide to yield a carbohydrate-lipidized antibody, which was eluted from the final PD-10 column with PBS. Sup T1 cells were maintained in 24-well plates 25 (100,000 cells per ml, in 2 ml of modified RPMI 1640 culture medium). Cells were kept in culture with either: (1) no additional treatment (two controls), (2) in the presence of added native anti-Tat antibody (15 fig/ml), or (3) in the presence of the lipidized anti-Tat antibody (11.7 Mg/ml) 30 during the first five days of the experiment. At the end of the first day, HIV-l IIIB was added to one well of control cells and to the cultures containing native anti-Tat antibody-treated cells or lipidized anti-Tat antibody-treated cells. Viable cells were counted daily. The untreated, HIV-infected 35 cells grew up to a density of approximately 500,000 cells per ml, and their number began to decrease after approximately eight days due to the cytotoxic effect of the virus. 2 5 5 0 4 WO 94/01131 PCT/ US93/06599 35 Uninfected cells grew up to a density of approximately 1,000,000 cells per ml. Treatment of infected cells with the native anti-Tat antibody did not protect the cells from the cytotoxic effect of the virus. In contrast the lipidized 5 anti-Tat antibody led to an almost complete protection of the cells from the cytopathic effects of the HIV-1 virus. This protection continued for at least about 5 days after the treatment with the lipidized antibody was interrupted. The results are presented in Fig. 3. 10 In another experiment, Sup T1 cells were maintained in culture as described in the previous example and kept in culture without any treatment and without any infection, infected with HIV-1 IIIB with no treatment, treated with the native anti-Tat antibody (1 Mg/ml) and infected, or treated 15 with the lipidized anti-Tat antibody (1 ng/ml) and infected. In the last three conditions, the virus was added at the end of the first day in culture. In the last two conditions, the native or lipidized antibody was present from day 1 until day 7. 20 The data presented in Table II show that, while the native anti-Tat antibody has little if any effect on viable cell number and reverse transcriptase activity, the lipidized antibody induced a significant protection of the cells in culture from the cytopathic effect of the virus and a 25 significant decrease in reverse transcriptase activity. The latter suggests that the lipidized antibody could inhibit intracellular HIV-1 replication. 2 5 5 0 4 3 WO 94/01131 PCT/US93/06599 36 10 25 TABLE II Effect of a Lipidized Anti-Tat Antibody on Viable Cell Number and Reverse Transcriptase Activity in Sup T1 Cells Infected with HIV-1 Viable Cells (xlO6) Days in Culture Conditions 15 Untreated, Uninfected 1. 15 1. 28 1. 52 1. 63 1.69 1. 76 1. 72 Untreated, Infected 1. 12 1. 2 1. 18 1. 12 0.92 0. 64 0. 51 20 Treated with native anti-Tat Ab Infected 1. 12 1. 2 1. 21 1. 15 0.96 0. 67 0. 51 Treated with lipidized 1. 15 1. 26 1. 3 1. 36 1.17 0. 99 0. 75 anti-Tat Ab Infected Reverse Transcriptase Activity (cpm/109 cells) Days in Culture 30 1235678 Conditions Untreated, Uninfected 2 2 12 2 11 35 Untreated, Infected 3 2 4 175 264 337 367 Treated with native anti-Tat Ab Infected 2 2 3 151 237 259 331 40 Treated with lipidized 3 2 2 57 135 179 184 anti-Tab Ab Infected HIV-l-infected SupTl cells were treated daily with anti-Tat antibody in native or lipidized form or with rsCD4 45 (al? proteins used at l ng/ml) startin from Day 1 before audition of HIV-l virus containing supernatants until 10 days post infection. Cell numbers and reverse transcriptase activity (RT) in the culture medium were determined every day starting from Day 2 post-infection. By Day 10, the native 50 anti-Tat still had no significant effect on either cell counts WO 94/01131 37 255 043 PCT/US93/06599 or RT activity, whereas the lipidized anti-Tat antibody increased cell viability as compared to untreated, infected cells by approximately 70% and decreased RT activity by approximately the same extent. Cultures were continued for 3 5 days without further addition of antibodies. Effects of the lipidized anti-Tat persisted for the 3 days, indicating that the lipidized anti-Tat antibodies had accumulated in the cells in amounts high enough to provide sustained protection against viral infection/replication. The magnitude of the effects of 10 the lipidized anti-Tat antibody on cell viability and RT activity were very similar to those observed with rsCD4 at the same dose. Increasing the concentration of the lipidized anti-Tat antibodies to 10 ng/xal did not induce further decrease in RT activity. 15 Example 3 Ability of Lipidized Anti-Tat to Inhibit the Transcriptional Activity of Tat on the HTV-1 LTR A HeLa cell line stably transfected with a 20 polynucleotide expressing CD4, the membrane receptor mediating HIV-1 infection, and also containing a reporter construct comprising an HIV-1 long terminal repeat (LTR) in operable linkage to and driving transcription of a linked reporter gene (chloramphenicol acetyltransferase; CAT). These cells (HLCD4-25 CAT) are susceptible to HIV-l infection which produces functional Tat protein; the binding of newly synthesized Tat to the HIV-1 LTR leads to transcription of the linked CAT gene. Thus, the magnitude of CAT expression is approximately proportional to the extent of HIV-l infection and the activity 30 of Tat protein in the cells. Cultured HeLa cells (3 x 10s cells/ml in DMEM with 10% fetal bovine serum) were exposed to the same concentrations (1 or 10 /ig/ml) of various antibodies (in native or lipidized form) or recombinant soluble CD4 (rsCD4) for 1 hour and were 35 extensively washed prior to addition of HIV-containing cell culture superoatants (100 Ml)* Twenty-four hours later the cells were harvested and CAT expression was measured by the method of Ho et al. (1984). Each experiment was run in quadruplicate and conducted four different time. Fig. 4 shows 40 that the lipidized anti-Tat antibody significantly inhibited 255 043 PCT / US93/06599 CAT activity (by approximately 75%), whereas native (unlipidized) anti-Tat antibody, lipidized anti-gpl20 antibody, or rsCD4 were far less effective in inhibiting CAT activity. These data indicate that lipidized anti-Tat was able to 5 specifically bind its intracellular target, Tat, and inhibit the target's activity as a transcriptional activator of the LTR/reporter gene construct. Moreover, the data showing passage of the lipidized anti-Tat antibody into HeLa cells indicates that the transport 10 mechanism does not likely require endosome formation, since HeLa cells are reported to undergo little if any phagocytosis. WO 94/01131 Example 4 Preparation of Lipidized Immunoglobulins Reactive with an 15 Intracellular Protein Glycyldioctadecylamide is obtained by linking a glycine residue to dioctadecylamine according to the method described by Behr et al. (1989) Proc. Natl. Acad. Sci. (U.S.A.) 86: 6982, which is incorporated herein by reference. 20 Benzyloxycarbonyl-glycyl-p-nitrophenol at 1 equivalent and triethylamine at 1.1 equivalents in CH2C12 are reacted for 5 hours, followed by addition of H2, 10% Pd/C in CH2Cl2/EtOH and reaction for 1 hour. 25 Anti-Human c-Mve la Glycosylated murine immunoglobulins that bind specifically to human c-myc protein are prepared by separately culturing the hybridoma cell lines MYC CT9-B7.3 (ATCC CRL 1725), MYC CT 14-G4.3 (ATCC CRL 1727), and MYC 1-9E10.2 (ATCC 30 CRL 1729) in RPMI 1640 with 10 percent fetal bovine serum under specified conditions (Evan et al. (1985) Mol. Cell. Biol. 3610, incorporated herein by reference) and the monoclonal antibodies secreted are collected and purified by conventional methods known in the art. 35 About 2 mg of each purified monoclonal antibody are dissolved in 400 /xl of 300 mM NaHC03 in a 1.5 ml Eppendorf vial. Fifty fil of a freshly prepared NaI04 solution (42 mg/ml in H20) is added and the vial is wrapped in aluminum foil and 2 5 5 0 4 3 WO 94/01131 PCT/US93/06599 39 gently shaken for 90 min. at room temperature. The reaction medium is then loaded on a PD-10 column (Pharmacia) previously equilibrated with 10 mM Na2C03 (fraction 1), and the column is eluted with 500 nl fractions. The fraction(s) containing at 5 least approximately 500 ng of IgG as measured using the Bradford protein assay are collected. A solution of glycyldioctadecylamide in DMSO is prepared (5 mg of the lipid into 1 ml of DMSO, vigorously vortexed for several minutes). Under those conditions the 10 lipid is not fully dissolved. Fifty nl of this solution is taken carefully and added to 350 til of the purified IgG fractions obtained as described above, in an Eppendorf vial. The vial is wrapped in aluminum foil, and the mixture is gently shaken for 20 h at room temperature. 15 one hundred nl of a solution of NaBH4 (10 mg/ml in H20) is then added. After one hour, 40 /zl of a solution of ethanolamine (15 /j1 in 1 ml H20) is added. After an additional 1 h, the reaction mixture is loaded on a PD-10 column previously equilibrated in PBS. The fraction containing the 20 lipidized murine anti-human-myc IgG (between 3 and 3.5 ml) is collected and stored on ice. Anti-HMG CoA Reductase la Glycosylated murine immunoglobulins that bind 25 specifically to the intracellular enzyme HMG CoA reductase are prepared by separately culturing the hybridoma cell line A9 (ATCC CRL 1811) in DMEM with 4.5 g/1 glucose, 5% horse serum and 2.5% fetal bovine serum as described (Goldstein et al. (1983) J. Biol. Chem. 258: 8450, incorporated herein by 30 reference) and the monoclonal antibodies secreted are collected and purified by conventional methods known in the art. About 2 mg of each purified monoclonal antibody are dissolved in 400 ftl of 300 mM NaHC03 in a 1.5 ml Eppendorf vial. Fifty /xl of a freshly prepared NaI04 solution (42 mg/ml 35 in H20) is added and the vial is wrapped in aluminum foil and gently shaken for 90 min. at room temperature. The reaction medium is then loaded on a PD-10 column (Pharmacia) previously equilibrated with 10 mM Na2C03 (fraction 1), and the column is WO 94/01131 2 40 eluted with 500 nl fractions. The fraction(s) containing at least approximately 500 nq of IgG as measured using the Bradford protein assay are collected. A solution of glycyldioctadecylamide in DMSO is 5 prepared (5 mg of the lipid into 1 ml of DMSO, vigorously vortexed for several minutes). Under those conditions the lipid is not fully dissolved. Fifty /xl of this solution is taken carefully and added to 350 /zl of the purified IgG fractions obtained as described above, in an Eppendorf vial. 10 The vial is wrapped in aluminum foil, and the mixture is gently shaken for 20 h at room temperature. One hundred nl of a solution of NaBH4 (10 mg/ml in H20) is then added. After one hour, 40 nl of a solution of ethanolamine (15 jul in 1 ml H20) is added. After an additional 15 l h, the reaction mixture is loaded on a PD-10 column previously equilibrated in PBS. The fraction containing the lipidized anti-HMG CoA reductase IgG (between 3 and 3.5 ml) is collected and stored on ice. 20 Example 5 Preparation of Lipidized Immunoglobulins Reactive with a Transmembrane Protein Glycyldioctadecylamide is obtained by linking a glycine residue to dioctadecylamine according to the method 25 described by Behr et al. (1989) Proc. Natl. Acad. Sci. (U.S.A.\ ££: 6982, which is incorporated herein by reference. Benzyloxycarbonyl-glycyl-p-nitrophenol at 1 equivalent and triethylamine at 1.1 equivalents in CH2C12 are reacted for 5 hours, followed by addition of H2, 10% Pd/C in CH2Cl2/EtOH and 30 reaction for 1 hour. Anti-Ras lg Glycosylated murine immunoglobulins that bind specifically to ras oncogene protein are prepared by separately 35 culturing the hybridoma cell line 142-24E5 (ATCC HB 8679; U.S. Pats. 5,015,571 and 5,030,565, incorporated herein by reference) in DMEM with 4.5 g/1 glucose, 2^M L-glutamine, ImM sodium pyruvate, non-essential amino acids, lxBME vitamins, o.l WO 94/01131 41 2^AiU3 mM hypoxanthine, 0.032mM thymidine, 0.05 mg/ml gentamicin, and 10% fetal bovine serum, and the hybridoma cell MX (ATCC HB 9158) in Iscove(s DMEM with 1% L-glutamine and HT and 10 percent fetal bovine serum under specified conditions (U.S. 5 Patent 4,820, 631, incorporated herein by reference) and the monoclonal antibodies secreted from the hybridoma lines are collected and purified by conventional methods known in the art. About 2 mg of each purified monoclonal antibody are 10 dissolved in 400 /til of 300 mM NaHC03 in a 1.5 ml Eppendorf vial. Fifty Ml of a freshly prepared NaI04 solution (42 mg/ml in H20) is added and the vial is wrapped in aluminum foil and gently shaken for 90 min. at room temperature. The reaction medium is then loaded on a PD-10 column (Pharmacia) previously 15 equilibrated with 10 mM Na2C03 (fraction 1), and the column is eluted with 500 nl fractions. The fraction(s) containing at least approximately 500 Mg of IgG as measured using the Bradford protein assay are collected. A solution of glycyldioctadecylamide in DMSO is 20 prepared (5 mg of the lipid into 1 ml of DMSO, vigorously vortexed for several minutes). Under those conditions the lipid is not fully dissolved. Fifty Ml of this solution is taken carefully and added to 350 Ml of the purified IgG fractions obtained as described above, in an Eppendorf vial. 25 The vial is wrapped in aluminum foil, and the mixture is gently shaken for 20 h at room temperature. One hundred Ml of a solution of NaBH4 (10 mg/ml in H20) is then added. After one hour, 40 /xl of a solution of ethanolamine (15 Ml in 1 ml H20) is added. After an additional 30 1 h, the reaction mixture is loaded on a PD-10 column previously equilibrated in PBS. The fraction containing the lipidized murine anti-ras IgG (between 3 and 3.5 ml) is collected and stored on ice. Hybridoma cell lines referred to in the above 35 examples may be obtained from American Type Culture Collection, Rockville, MD (ATCC Cell Lines and Hybridomas (1992) 7th Ed, which is incorporated herein by reference). 255 043 WO 94/01131 PCT/US93/06599 42 Example S Lipidization of a Transmembrane Enzyme The enzyme gamma-glutamyltranspeptidase (GGT: EC 2.3.2.2) is a widely distributed enzyme that catalyzes the 5 degradation of glutathione and other y-glutamyl compounds by hydrolysis of the 7-glutamyl moiety or by its transfer to a suitable acceptor. GGT is a heterodimeric glycoprotein, which is synthesized as a precursor protein that is glycosylated and cleaved into the two subunits of the mature enzyme. GGT is 10 anchored to the cell membrane through the N-terminal portion of its heavy subunit. The active site of the enzyme lies on the extracellular portion of the molecule, which is heavily glycosylated. GGT is separately purified from rat kidney and a 15 cultured human hepatoma cell line according to procedures described previously in the art (Barouki et al. (1984) J. Biol. Chem. 259; 7970; Curthoys and Hughey (1979) Enzvme 24: 383; Matsuda et al. (1983) J. Biochem. 93: 1427; Taniguchi et al. (1985) J. Natl. Cancer Inst. 21'- 841; Tate and Meister (1985) 20 Methods Enzvmol. H2.: 400; and Toya et al. (1983) Ann. N.Y. Acad. Sci. 417: 86, which are incorporated herein by reference). About 1 mg of each of the purified rat and human GGT preparations are dissolved in 400 /xl of 300 mM NaHC03 in a 1.5 25 ml Eppendorf vial. Fifty /xl of a freshly prepared NaI04 solution (42 mg/ml in H20) is added and the vial is wrapped in aluminum foil and gently shaken for 60 min. at room temperature. The reaction medium is then loaded on a PD-10 column (Pharmacia) previously equilibrated with 10 mM Na2C03 30 (fraction l), and the column is eluted with 500 pi fractions. The fraction(s) containing at least approximately 100 ng of GGT as measured using the Bradford protein assay are collected. A solution of glycyldioctadecylamide in DMSO is prepared (5 mg of the lipid into 1 ml of DMSO, vigorously 35 vortexed for several minutes). Under those conditions the lipid is not fully dissolved. Fifty nl of this solution is taken carefully and added to 350 ^1 of the purified GGT fractions obtained as described above, in an Eppendorf vial. WO 94/01131 3 43 The vial is wrapped in aluminum foil, and the mixture is gently shaken for 20 h at rcnm temperature. One hundred Ml of a solution of NaBH4 (10 mg/ml in H20) is then added. After one hour, 40 Ml of a solution of 5 ethanolamine (15 Ml in 1 ml H20) is added. After an additional 1 h, the reaction mixture is loaded on a PD-10 column previously equilibrated in PBS. The fraction containing the lipidized human and rat GGT (between 3 and 3.5 ml) is collected and stored on ice. 10 The lipidized human and rat GGT fractions are assayed for 7-glutamyltranspeptidase activity by conventional assay procedures (Tate and Meister (1983) op.cit.. incorporated herein by reference) and the specific activity of the lipidized human GGT and lipidized rat GGT is determined. 15 The lipidized human and rat GGT is radiolabeled by iodination with 125I using chloramine T and approximately 50 m9 of the radioiodinated lipidized GGT is administered to rats by intraperitoneal injection. After 24 hours, the rats are sacrificed and tissue samples removed for autoradiography to 20 determine the pattern of localization of the lipidized GGT in the various organs. Example 7 Lipitiieatipn of an Anti-Actin ftntifrpdy and Intracellular 25 Immunostainlna In order to demonstrate that lipidized antibodies can localize intracellularly in living cells and bind intracellular targets, an anti-actin antibody was lipidized and evaluated for its ability to penetrate cultured Swiss 3T3 fibroblasts and 30 bind to the cytoskeletal protein actin. Native anti-actin antibody (unlipidized) was used as a control. Protein A-purified rabbit anti-actin polyclonal antibodies were lipidized according to the following procedure. A lipoamine, glycyldioctadecylamide, was covalently linked to 35 the carbohydrate moieties of the anti-actin antibodies by periodate oxidation-sodium borohydride reduction. Antibodies were dissolved in 0.8 ml of 300 mM NaHC03 at a concentration of approximately 0.2 to 1.0 mg/ml. Fifty Ml of a freshly prepared •J /_ b b 0 4 3 WO 94/01131 PCT/US93/06599 44 aqueous solution of NaI04 (42 mg/ml) were added and the incubation vials were wrapped in aluminum foil and gently shaken for 90 minutes at room temperature. The reaction mixture was then purified on a PD-10 column (Pharmacia, 5 Pi scat away, NJ) equilibrated in and eluted with 10 mM Na2C03. Fifty y.1 of a 10 mg/ml solution of glycyldioctadecylamide in benzene are added to the fraction containing the antibodies (e.g., as determined by A28o monitoring, Bradford assay) and the resulting reaction was incubated for 20 hours at room 10 temperature with gentle shaking. One hundred /xl of a freshly prepared aqueous solution of NaBH4 (10 mg/ml) was then added and inubated at room temperature for one hour, followed by addition of 50 /xl of ethanolamine solution (15 /ul ethanolamine dissolved in 1 ml of H20). After an additional hour at room 15 temperature, the resultant lipidized antibodies were purified by chromatography on a PD-10 column equilibrated with phosphate-buffered saline. ELISA Aggflyg 20 were evaluated for their binding affinity for specific antigen relative to native (unlipidized) anti-actin or anti-Tat antibody by ELISA assay. Lipidization of either the anti-actin antibody or the anti-Tat antibody did not produce a measurable loss of affinity of the antibodies for their respective 25 antigens as compared to their native (unlipidized) antibody. Intracellular Immunostainina are able to bind intracellular actin in live cells, lipidized anti-actin antibody or native anti-actin antibody were 30 contacted with cultured Swiss 3T3 cells for 1 hour, followed by extensive washing to remove residual anti-actin antibodies. The cells were subsequently fixed and permeabilized and the anti-actin antibodies were detected with a fluorescent-labeled secondary antibody. While no specific staining could be 35 detected in cells preincubated with the native (unlipidized) anti-actin antibody, specific actin staining (e.g., stained actin cables) was clearly evident in cells preincubated with the lipidized anti-actin antibodies. The staining pattern Lipidized anti-actin and lipidized anti-Tat (supra) To demonstrate that lipidized anti-actin antibodies WO 94/01131 2 5 5 0 4 3 PCT/US93/06599 45 observed with the lipidized anti-rctin antibody applied prior to fixation was similar to that seen using native (unlipidized) anti-actin antibody incubated with the cells following fixation and permeabilization. These data demonstrate that the 5 lipidized anti-actin antibodies were able to reach and bind intracellular actin, and that they could still be recognized and bound by the labeled secondary antibodies, indicating that they were functional and substantially intact. Although the present invention has been described in some detail by way of illustration for purposes of clarity of understanding, it will be apparent that certain changes and 15 modifications may be practiced within the scope of the claims. </div>

Claims

<div class="application article clearfix printTableText" id="claims"> 255 043 PCT / US93/06599 £1&IM£ 1. A method for modifying the pharmacokinetic characteristics of a protein, comprising the steps of: 5 attaching a lipid substituent to the protein by a covalent linkage to produce a lipidized protein; and recovering the lipidized protein. 2. A method according to Claim 1, wherein the lipid 10 substituent is a lipoamine. 3. A method according to Claim 2, wherein the step of attaching further comprises the steps of oxidizing a carbohydrate on a glycosylated 15 polypeptide to produce an oxidized glycoprotein; and reacting the oxidized glycoprotein with a lipoamine under suitable reaction conditions to form a lipidized protein. 4. A method according to Claim 2, wherein the lipoamine is a 20 straight-chain lipoamine according to the formula: NH2-R-(CH2)n-CH3 where R is selected from the group consisting of: 25 disubstituted alkyl (alkylene); 1,4-disubstituted cyclohexyl; disubstituted aryl (arylene); amido group of the formula -(CHRj^)-CO-NH- wherein Ra is hydrogen or an amino group; alkylcarbonyl; and phosphate diester; n is 1-50. 30 5. A method according to Claim 2, wherein the lipoamine is a branched-chain lipoamine according to the formula: NH2-R,-(CH2)n-CH3 35 (CH2)m ch3 40 where R' is: a trisubstituted alkyl; a trisubstituted aryl; an amido group of the formula -(CHR1)-CO-N< wherein R2 is WO 94/01131 V'O 94/0 J131 PCT/ US93/06599 25 5 0 4 3 hydrogen or an amino group; an imino group of the formula -CHR2-NH-CH< wherein R2 is hydrogen or an amino group or an imino group of the formula -CH2-N<; or a phosphate diester; m is 1-50; n is 1-50; and m and n are selected independently. 5 6. A method according to claim 5, wherein the branched-chain lipoamine is glycyldioctadecylamide. 7. A method according to Claim 1, wherein the protein is a 10 naturally-occurring glycoprotein. 8. A method according to Claim 1, wherein the protein is encoded by an immunoglobulin superfamily gene. 15 9. A method according to Claii.. 8, wherein the immunoglobulin superfamily gene encodes a m or 7 heavy chain. 10. A method according to Claim 7, wherein the naturally-occurring glycoprotein is an antibody. 20 11. A method according to Claim 10, wherein the antibody is a monoclonal antibody. 12. A method according to Claim 1, wherein the lipidized 25 protein comprises at least one lipoamine residue linked to a carbohydrate side chain. kwo 94/01131 4*;PCT/US93/06599;25 5 0 4 3;10;13. A composition for therapy or prophylaxis of a disease, comprising a therapeutically effective dosage of a lipidized protein.;15 14. A composition according to Claim 13, wherein the lipidized protein is an antibody.;15. A composition according to Claim 14, wherein the antibody binds to an intracellular protein.;20;16. a composition according to Claim 15, wherein the intracellular protein is a viral-encoded protein.;17* A composition according to Claim 16, wherein the viral-25 encoded protein is a Tat protein encoded by HIV-l. 18. A composition for prophylaxis, comprising a prophylactically effective dosage of a lipidized antibody. 30 19. A composition comprising a lipidized antibody linked to a diagnostic reporter. 20. A composition according to Claim 13, containing a carbohydrate-linked lipidized protein. 21. A composition according to Claim 20, wherein the carbohydrate-linked lipidized protein is a carbohydrate-linked lipidized immunoglobulin. ■ 35 2 3 DEC 1996 WO 94/01131 49 PCT/ US93/06599 25 5 0 A 3 22. A pharmaceutically acceptable composition comprising a carbohydrate-linked lipidized immunoglobulin, and an excipient. 23. A method for diagnosing a pathological condition, comprising the steps of: administering a lipidized antibody comprising a diagnostic reporter to a patient; and detecting a location at which the diagnostic reporter is preferentially localized. 10 </div>